Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1002 for Prevention of Major Adverse Kidney Events After Cardiac Surgery
2018-000757-49Phase 3Terminated
- Sponsor
- Quark Pharmaceuticals
- Start
- Aug 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) and major adverse kidney events (MAKE) comparing QPI-1002 IV infusion with Placebo IV infusion (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Aug 2018; status: terminated.
02
Drugs
teprasiran
03
Conditions
acute kidney failure (AKF)major adverse kidney events (MAKE)
Beyond the preview
Go deeper on 2018-000757-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000757-49.